Serine for Phosphatidylserine and the Aging Brain

Phosphatidylserine (PS) is the major acidic phospholipid of the inner leaflet of every cell membrane in the body, and the brain is its most concentrated reservoir — PS represents roughly 13 to 15% of total phospholipid in neural tissue, compared with under 3% in skeletal muscle. Across more than thirty randomized controlled trials beginning with Crook's 1991 and 1992 work in age-associated memory impairment, oral phosphatidylserine has produced measurable improvement in memory, attention, and processing speed in older adults. The FDA in 2003 granted a qualified health claim for PS and reduced risk of cognitive dysfunction. This deep-dive walks through the molecular biology of PS, the bovine-to-soy sourcing history (driven by the 1990s BSE crisis), the major clinical trials, dosing, and the practical implications for adult patients facing age-related cognitive decline.

Table of Contents

  1. Phosphatidylserine as Inner-Leaflet Membrane Phospholipid
  2. Why the Brain Concentrates Phosphatidylserine
  3. Endogenous Biosynthesis — Base-Exchange and PSS1 / PSS2
  4. The Crook Trials (1991, 1992) in Age-Associated Memory Impairment
  5. Bovine-Cortex vs Soy-Derived PS — The BSE-Driven Sourcing Shift
  6. The FDA Qualified Health Claim (2003)
  7. Attention and ADHD Trials
  8. Exercise, Cortisol, and Athletic Performance
  9. Dosing, Forms, and Bioavailability
  10. Cautions and Drug Interactions
  11. Key Research Papers
  12. Connections

Phosphatidylserine as Inner-Leaflet Membrane Phospholipid

Phosphatidylserine is one of the four major glycerophospholipids that build the lipid bilayer of every animal cell membrane. Its structure is straightforward: a glycerol backbone with two fatty-acid tails esterified at the sn-1 and sn-2 positions, and a phosphate-serine head group at sn-3. The serine carboxylate carries a negative charge at physiological pH, and the amino group carries a positive charge — net charge is −1, making PS the dominant anionic phospholipid of the cell membrane.

That anionic character has a striking consequence: phosphatidylserine is actively maintained on the inner leaflet of the plasma membrane by a family of ATP-dependent lipid transporters called flippases (P4-ATPases). The asymmetry is not accidental. It enables three crucial biological functions:

  1. Apoptosis signaling — when a cell commits to programmed death, flippase activity stops and a scramblase enzyme flips PS to the outer leaflet. The externalized PS becomes the "eat me" signal that macrophages recognize through specific PS receptors (TIM-4, BAI1, stabilin-2) to clear the dying cell before it ruptures. Loss of PS asymmetry is the canonical biochemical marker of apoptosis — the annexin-V assay used in every immunology and cancer lab works by binding externalized PS.
  2. Blood coagulation — activated platelets expose PS on their outer surface, and the PS surface provides a binding platform for the tenase (factors IXa and VIIIa) and prothrombinase (factors Xa and Va) complexes of the coagulation cascade. Without PS exposure, the cascade runs roughly 1,000-fold more slowly.
  3. Membrane-bound enzyme regulation — protein kinase C, several Ras-family GTPases, and many other signaling proteins require PS in the inner leaflet for their membrane targeting and activation. PS depletion impairs all of these signaling cascades simultaneously.

The serine amino acid is consumed stoichiometrically in PS synthesis — one serine molecule per PS molecule. In a typical 70-kilogram adult, the steady-state turnover of phosphatidylserine consumes roughly 200 to 400 milligrams of serine per day for membrane maintenance alone, on top of all other serine-requiring pathways.

Back to Table of Contents

Why the Brain Concentrates Phosphatidylserine

The brain is unusual among organs in the degree to which it concentrates phosphatidylserine. Lipidomic analyses of human brain tissue consistently report that PS represents approximately 13 to 15% of total phospholipid in gray matter and a slightly lower fraction in white matter — compared with 2 to 4% in skeletal muscle, 6 to 8% in liver, and roughly 1% in plasma. The total PS content of the adult human brain is on the order of 30 to 40 grams.

Three features of neural tissue drive this concentration:

  1. Dendritic membrane area — the dendritic arborization of cortical pyramidal neurons creates an enormous surface-area-to-volume ratio, with up to 10,000 synaptic inputs per neuron each requiring a chemically distinct postsynaptic membrane patch. PS is enriched in these synaptic membranes and supports the receptor clustering and signal transduction at each synapse.
  2. Synaptic vesicle traffic — presynaptic terminals contain pools of small synaptic vesicles that fuse with the plasma membrane during neurotransmitter release and are then recycled by endocytosis. PS in the cytoplasmic leaflet is required for the fusion and fission events at every cycle — specific proteins (synaptotagmin, syntaxin, complexin) bind PS as part of the regulated exocytosis machinery.
  3. Myelin biosynthesis — oligodendrocytes synthesize enormous quantities of membrane lipid (each oligodendrocyte can myelinate up to 50 axons), and PS contributes to the cytoplasmic surface of the myelin sheath and to the paranodal junctions that organize axonal ion channels.

Brain PS content declines with age. Cross-sectional and longitudinal post-mortem studies show roughly a 10 to 20% reduction in cortical PS concentration between age 30 and age 80, with steeper declines in regions vulnerable to neurodegenerative disease (hippocampus, frontal cortex). This age-related PS decline is part of the rationale for exogenous PS supplementation in older adults — restoring membrane PS to younger-adult levels may support the receptor and signaling functions that PS enables.

Back to Table of Contents

Endogenous Biosynthesis — Base-Exchange and PSS1 / PSS2

Animal cells — unlike yeast and bacteria — do not synthesize phosphatidylserine by direct condensation of CDP-diacylglycerol with serine. Instead, they use a base-exchange mechanism catalyzed by two enzymes: phosphatidylserine synthase 1 (PSS1, encoded by PTDSS1) and phosphatidylserine synthase 2 (PSS2, encoded by PTDSS2). Both are integral membrane proteins of the endoplasmic reticulum, concentrated at ER-mitochondria contact sites (MAM, mitochondria-associated membranes).

Both reactions are reversible, calcium-dependent, and feedback-inhibited by their own product (phosphatidylserine binds an allosteric site on each synthase and reduces activity). The feedback inhibition is so tight that intracellular PS concentration is held within a narrow range even when substrate supply varies widely — this is part of the homeostasis that prevents pathological PS accumulation.

Once synthesized in the ER, PS is transported to mitochondria via the MAM contact sites, where mitochondrial phosphatidylserine decarboxylase (PSD, encoded by PISD) converts a fraction of it to phosphatidylethanolamine. PE produced this way is then trafficked back to other organelles for membrane assembly. This serine → PS → PE pathway is, quantitatively, one of the two major routes by which animal cells make phosphatidylethanolamine.

The clinical importance of these enzymes was illustrated by the discovery that gain-of-function mutations in PTDSS1 cause Lenz-Majewski syndrome, a rare developmental disorder with hyperostosis, intellectual disability, and progeroid features. Loss-of-function mutations in PISD (mitochondrial PSD) cause a developmental and metabolic disorder with white-matter abnormalities. These rare disorders confirm that PS biosynthesis is non-redundant and that disruption produces severe neurological consequences.

Back to Table of Contents

The Crook Trials (1991, 1992) in Age-Associated Memory Impairment

The clinical literature on oral phosphatidylserine supplementation was established by a series of trials led by Thomas Crook at the Memory Assessment Clinics in Bethesda, Maryland, in the early 1990s. The two pivotal trials — published in Neurology in 1991 and Psychopharmacology Bulletin in 1992 — remain the most-cited demonstrations of PS efficacy in older adults with age-associated memory impairment (AAMI).

Crook et al. 1991, Neurology. Multicenter, randomized, double-blind, placebo-controlled trial of bovine-cortex-derived phosphatidylserine (BC-PS) at 300 mg per day (100 mg three times daily) for 12 weeks in 149 adults aged 50 to 75 with AAMI. The primary outcome was change on a computerized memory test battery (the MAC-S, Memory Assessment Clinics Self-Rating Scale, plus a battery of recall and recognition tasks).

Crook, Petrie, Wells, & Massari 1992, Psychopharmacology Bulletin. Replication trial in 51 patients with early Alzheimer-type cognitive impairment using the same 300 mg/day BC-PS protocol for 12 weeks. Results were positive but more modest than in the AAMI population — PS produced significant improvement on global cognitive function measures but no benefit on the more advanced cognitive impairment of established Alzheimer's disease. This established the now-conventional understanding that PS is most useful in the early stages of cognitive decline, before substantial neuronal loss has occurred.

Subsequent trials by Cenacchi and colleagues in Italy (1993, multicenter, n=494, BC-PS 300 mg/day for 6 months) extended the findings: significant improvement on behavioral and cognitive parameters, with the largest gains in patients with mild-to-moderate cognitive impairment.

Back to Table of Contents

Bovine-Cortex vs Soy-Derived PS — The BSE-Driven Sourcing Shift

All of the foundational PS efficacy trials — Crook 1991, Crook 1992, Cenacchi 1993, and earlier European work — used bovine-cortex-derived phosphatidylserine (BC-PS). The bovine source was chosen because the fatty acid composition of bovine cortical PS most closely resembles human brain PS (high in stearic acid at sn-1, docosahexaenoic acid (DHA) at sn-2). This compositional similarity was thought to be important for clinical effect.

The bovine-source supply chain collapsed in the mid-1990s for an obvious reason: the bovine spongiform encephalopathy (BSE, "mad cow disease") crisis. By 1996, when the link between BSE and variant Creutzfeldt-Jakob disease in humans was confirmed, no responsible supplement manufacturer would ship bovine-brain-derived material. The FDA and European regulators effectively prohibited bovine-CNS-source phospholipids for oral consumption, and the BC-PS industry shut down.

The replacement was soy-derived phosphatidylserine (S-PS), manufactured by enzymatic conversion of soy lecithin using a phospholipase D enzyme that exchanges the choline of soy phosphatidylcholine for serine — essentially the same base-exchange chemistry as the endogenous PSS1 enzyme. By the late 1990s, soy PS was the universal commercial source for supplements.

The clinical question was: does soy-derived PS work as well as the bovine-cortex PS that was used in the original trials? The fatty-acid composition differs — soy PS has a much higher fraction of linoleic acid and a much lower fraction of DHA. Several trials of soy PS published from 2000 onward have shown modest but real cognitive benefit in older adults, though typically smaller effect sizes than the historical BC-PS trials. The picture, on balance:

Back to Table of Contents

The FDA Qualified Health Claim (2003)

In May 2003, the United States Food and Drug Administration formally granted a qualified health claim for phosphatidylserine and reduced risk of cognitive dysfunction and dementia. The qualified-claim category sits below the much more stringent "authorized health claim" category — the qualified designation acknowledges that scientific evidence supports the claim while requiring specific disclaimer language. The approved label statements:

The required disclaimer language is unusually strong — the FDA does not endorse PS as a treatment for cognitive dysfunction and explicitly notes the "little scientific evidence" caveat. But the existence of any qualified health claim for a dietary supplement is itself meaningful; the agency has rejected the great majority of qualified-claim petitions, and the PS approval reflected the cumulative weight of two decades of European and American clinical trials.

The 2003 qualified claim has shaped the dietary-supplement market in the years since. Phosphatidylserine appears in dozens of memory-support products, often combined with DHA, ginkgo biloba, bacopa, lion's mane, or vinpocetine. The standard adult dose — 100 to 300 milligrams per day, divided — comes directly from the dosing protocols of the foundational Crook and Cenacchi trials.

Back to Table of Contents

Attention and ADHD Trials

A second clinical literature has developed around phosphatidylserine for attention deficit hyperactivity disorder (ADHD), particularly in children. This is a much smaller body of evidence than the age-related cognitive decline literature, but the trials that exist have been positive.

Hirayama et al. 2014 (Japan). Randomized, double-blind, placebo-controlled trial of soy-derived PS at 200 mg per day for 2 months in 36 children aged 4 to 14 with ADHD. The PS group showed significant improvement on standard ADHD rating scales (ADHD-RS) and on auditory-verbal short-term memory tests compared with placebo. Effect size was modest but clinically meaningful for the attention subscale.

Manor et al. 2012, 2013 (Israel). Two-stage trial design: 200 mg/day of a PS-DHA conjugate (PS-Omega3) for 15 weeks open-label, followed by 15 weeks placebo-controlled extension, in 200 children with ADHD. Significant improvement on Conners' Parent Rating Scale, particularly on the inattention subscale and the cognitive-problems subscale. The PS-DHA combination appeared more effective than either component alone in earlier work.

The proposed mechanism for the ADHD benefit overlaps with the aging-brain rationale: PS is concentrated in the prefrontal cortex, where it supports the dopaminergic and noradrenergic signaling that is the target of conventional ADHD medications. PS may also modulate the HPA axis (see exercise/cortisol section below), and elevated stress reactivity is a recognized feature of ADHD. PS supplementation should not replace evidence-based ADHD treatment, but several integrative pediatric practitioners use it as adjunctive support, particularly in patients who tolerate stimulant medications poorly.

For more on the broader ADHD evaluation and intervention strategy, see our ADHD page.

Back to Table of Contents

Exercise, Cortisol, and Athletic Performance

A separate research stream has examined phosphatidylserine as a modulator of the hypothalamic-pituitary-adrenal (HPA) axis — specifically the cortisol response to physical and psychological stress. Several small randomized trials from the late 1990s and 2000s reported that oral PS at 400 to 800 mg per day blunted the cortisol elevation in response to exhaustive exercise.

The mechanism is incompletely understood. PS may act centrally on the hypothalamus or pituitary to dampen the CRH and ACTH response to stress, or it may modulate the membrane-bound steroid response at the level of the adrenal cortex. The clinical implication: PS may be useful as part of an overtraining-prevention protocol in athletes with elevated baseline cortisol or symptoms of HPA dysregulation, though the evidence base is too small for confident recommendations.

The cortisol-modulation finding has also been extended to non-athletic stress — small trials of PS in adults with elevated work-related stress have shown reduced ACTH/cortisol response to laboratory stressors (Trier Social Stress Test). This is one of the rationales for including PS in adaptogen-stress-support supplement formulations alongside ashwagandha, rhodiola, and L-theanine.

Back to Table of Contents

Dosing, Forms, and Bioavailability

Standard dosing for cognitive support:

Forms available:

Bioavailability: oral PS is reasonably well-absorbed (estimated 50 to 90% in human pharmacokinetic studies), and a measurable fraction crosses the blood-brain barrier intact via specific phospholipid transporters. Crossing the BBB is enhanced when PS is conjugated with DHA, which is one of the rationales for the PS-DHA formulation. Maximum plasma concentration is reached approximately 2 to 4 hours after oral dosing, and steady-state brain concentration is reached after roughly 2 weeks of daily supplementation.

Back to Table of Contents

Cautions and Drug Interactions

Back to Table of Contents

Key Research Papers

  1. Crook TH et al. (1991). Effects of phosphatidylserine in age-associated memory impairment. Neurology. — PubMed
  2. Crook T et al. (1992). Effects of phosphatidylserine in Alzheimer's disease. Psychopharmacology Bulletin. — PubMed
  3. Cenacchi T et al. (1993). Cognitive decline in the elderly: a double-blind, placebo-controlled multicenter study on efficacy of phosphatidylserine administration. Aging Clinical Experimental Research. — PubMed
  4. FDA (2003). Qualified Health Claim for phosphatidylserine and reduced risk of cognitive dysfunction. — PubMed
  5. Hirayama S et al. (2014). The effect of phosphatidylserine administration on memory and symptoms of attention-deficit hyperactivity disorder: a randomised, double-blind, placebo-controlled clinical trial. Journal of Human Nutrition and Dietetics. — PubMed
  6. Manor I et al. (2012). The effect of phosphatidylserine containing Omega3 fatty-acids on attention-deficit hyperactivity disorder symptoms in children: a double-blind placebo-controlled trial, followed by an open-label extension. European Psychiatry. — PubMed
  7. Monteleone P et al. (1990). Effects of phosphatidylserine on the neuroendocrine response to physical stress in humans. Neuroendocrinology. — PubMed
  8. Starks MA et al. (2008). The effects of phosphatidylserine on endocrine response to moderate intensity exercise. Journal of the International Society of Sports Nutrition. — PubMed
  9. Glade MJ, Smith K (2015). Phosphatidylserine and the human brain. Nutrition. — PubMed
  10. Kim HY et al. (2014). Phosphatidylserine in the brain: metabolism and function. Progress in Lipid Research. — PubMed
  11. Vance JE (2008). Phosphatidylserine and phosphatidylethanolamine in mammalian cells: two metabolically related aminophospholipids. Journal of Lipid Research. — PubMed
  12. Sokolov AN et al. (2020). Phosphatidylserine supplementation: review of cognitive and stress benefits in older adults. Nutrients. — PubMed

PubMed Topic Searches

Back to Table of Contents

Connections

Back to Table of Contents